Tirzepatida: efeitos adversos e reganho ponderal após a interrupção do tratamento — revisão integrativa

Autores

  • Pedro Henrique Alves Faculdade de Princípios Militares - FPM
  • Régis Rodrigues Santana
  • Katiulcy Carvalho Oliveira
  • Ivan Silveira de Avelar
  • Juliana Pires Ribeiro
  • Álvaro Paulo Silva Souza
  • Marcelo Carneiro dos Santos
  • Brenda Kaoanna Borges de Souza
  • Luiz Gustavo Nunes de Lima
  • Nathalya Monteiro da Silva
  • Viviane Alves Ferreira Magalhães
  • Matheus Felipe de Jesus Miranda Barbosa

DOI:

https://doi.org/10.36557/2674-8169.2026v8n10p1107-1142

Palavras-chave:

Tirzepatida;, Eventos adversos, Segurança;, Obesidade;, Reganho de peso;, Descontinuação do tratamento.

Resumo

Introdução: A tirzepatida é um agonista dual dos receptores do polipeptídeo insulinotrópico dependente de glicose (GIP) e do peptídeo semelhante ao glucagon tipo 1 (GLP-1), utilizada no tratamento do diabetes mellitus tipo 2 e no controle crônico do peso corporal. Apesar de sua eficácia no controle glicêmico e na redução ponderal, a ampliação de seu uso torna relevante a compreensão dos eventos adversos associados ao tratamento e das repercussões decorrentes de sua interrupção. Objetivo: Analisar as evidências disponíveis acerca dos eventos adversos associados ao uso da tirzepatida e do reganho de peso corporal após a interrupção do tratamento. Métodos: Revisão integrativa da literatura, de caráter descritivo, realizada nas bases PubMed, LILACS e MEDLINE, contemplando estudos publicados entre janeiro de 2020 e 2026. Foram incluídos estudos originais realizados em seres humanos que avaliaram eventos adversos associados à tirzepatida e/ou reganho ponderal após sua interrupção. A busca identificou 964 registros; após remoção de duplicatas, triagem e avaliação dos textos completos, 18 estudos constituíram a amostra final. Resultados: Quatorze estudos avaliaram eventos adversos e quatro investigaram a evolução do peso corporal após a interrupção do tratamento. Os eventos adversos foram predominantemente gastrointestinais, especialmente náusea, diarreia e vômitos, geralmente de intensidade leve a moderada e mais frequentes durante o escalonamento da dose. Estudos de farmacovigilância identificaram sinais adicionais no período pós-comercialização, sem permitir inferências de incidência ou causalidade. Após a interrupção da tirzepatida, observou-se reganho ponderal desde os primeiros meses, com recuperação substancial do peso previamente perdido em parte dos participantes. A manutenção do tratamento esteve associada à maior preservação da perda ponderal, enquanto maior reganho foi acompanhado, em alguns estudos, por deterioração de parâmetros glicêmicos e cardiometabólicos. Considerações Finais: A tirzepatida apresenta perfil de tolerabilidade predominantemente caracterizado por eventos adversos gastrointestinais, enquanto sua interrupção está associada à recuperação de parte do peso previamente perdido e, em alguns estudos, à redução de benefícios metabólicos alcançados durante o tratamento. Esses achados evidenciam a relevância do acompanhamento longitudinal e indicam a necessidade de estudos com seguimento prolongado após a descontinuação para caracterizar a trajetória do reganho ponderal e suas repercussões metabólicas.

Downloads

Não há dados estatísticos.

Referências

COSKUN, Tamer; SLOOP, Kyle W.; LOGHIN, Corina; ALSINA-FERNANDEZ, Jorge; URVA, Shweta; BOKVIST, Krister B.; CUI, Xuewei; BRIERE, Daniel A.; CABRERA, Over; ROELL, William C.; KUCHIBHOTLA, Uma; MOYERS, Julie S.; BENSON, Charles T.; GIMENO, Ruth E.; D'ALESSIO, David A.; HAUPT, Axel. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism, v. 18, p. 3–14, 2018. DOI: 10.1016/j.molmet.2018.09.009.

WILLARD, Francis S.; DOUROS, Jonathan D.; GABE, Maria B. N.; SHOWALTER, Aaron D.; WAINSCOTT, David B.; SUTER, Todd M.; CAPOZZI, Megan E.; VAN DER VELDEN, Wijnand J. C.; STUTSMAN, Cynthia; CARDONA, Guemalli R.; URVA, Shweta; EMMERSON, Paul J.; HOLST, Jens J.; D’ALESSIO, David A.; COGHLAN, Matthew P.; ROSENKILDE, Mette M.; CAMPBELL, Jonathan E.; SLOOP, Kyle W. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, v. 5, n. 17, e140532, 2020. DOI: 10.1172/jci.insight.140532.

FRÍAS, Juan Pablo; NAUCK, Michael A.; VAN, Joanna; KUTNER, Mark E.; CUI, Xuewei; BENSON, Charles; URVA, Shweta; GIMENO, Ruth E.; MILICEVIC, Zvonko; ROBINS, Deborah; HAUPT, Axel. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. The Lancet, v. 392, n. 10160, p. 2180–2193, 2018. DOI: 10.1016/S0140-6736(18)32260-8.

ROSENSTOCK, Julio; WYSHAM, Carol; FRÍAS, Juan P.; KANEKO, Shizuka; LEE, Clare J.; FERNÁNDEZ LANDÓ, Laura; MAO, Huzhang; CUI, Xuewei; KARANIKAS, Chrisanthi A.; THIEU, Vivian T. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, v. 398, n. 10295, p. 143–155, 2021. DOI: 10.1016/S0140-6736(21)01324-6.

ABBASI, Jennifer. FDA green-lights tirzepatide, marketed as Zepbound, for chronic weight management. JAMA, v. 330, n. 22, p. 2143–2144, 2023. DOI: 10.1001/jama.2023.24539.

BRASIL. Agência Nacional de Vigilância Sanitária. Mounjaro® (tirzepatida): novo registro. Brasília, DF: Anvisa, 25 set. 2023. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/mounjaro-r-tirzepatida-novo-registro. Acesso em: 5 jan. 2026.

BRASIL. Agência Nacional de Vigilância Sanitária. Mounjaro® (tirzepatida): nova indicação. Brasília, DF: Anvisa, 9 jun. 2025. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/mounjaro-r-tirzepatida-nova-indicacao. Acesso em: 5 jan. 2026.

HEISE, Tim; DEVRIES, J. Hans; URVA, Shweta; LI, Jing; PRATT, Edward J.; THOMAS, Melissa K.; MATHER, Kieren J.; KARANIKAS, Chrisanthi A.; DUNN, Julia; HAUPT, Axel; MILICEVIC, Zvonko; COSKUN, Tamer. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care, v. 46, n. 5, p. 998–1004, 2023. DOI: 10.2337/dc22-1710.

PATEL, Hiren; KHUNTI, Kamlesh; RODBARD, Helena W.; BAJAJ, Harpreet S.; BRAY, Ross; KINDRACKI, Zbigniew; RODRÍGUEZ, Ángel. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes, Obesity and Metabolism, v. 26, n. 2, p. 473–481, 2024. DOI: 10.1111/dom.15333.

ARONNE, Louis J.; SATTAR, Naveed; HORN, Deborah B.; BAYS, Harold E.; WHARTON, Sean; LIN, Wen-Yuan; AHMAD, Nadia N.; ZHANG, Shuyu; LIAO, Ran; BUNCK, Mathijs C.; JOURAVSKAYA, Irina; MURPHY, Madhumita A. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, v. 331, n. 1, p. 38–48, 2024. DOI: 10.1001/jama.2023.24945.

PAGE, Matthew J.; MCKENZIE, Joanne E.; BOSSUYT, Patrick M.; BOUTRON, Isabelle; HOFFMANN, Tammy C.; MULROW, Cynthia D.; SHAMSEER, Larissa; TETZLAFF, Jennifer M.; AKL, Elie A.; BRENNAN, Sue E.; CHOU, Roger; GLANVILLE, Julie; GRIMSHAW, Jeremy M.; HRÓBJARTSSON, Asbjørn; LALU, Manoj M.; LI, Tianjing; LODER, Elizabeth W.; MAYO-WILSON, Evan; MCDONALD, Steve; MCGUINNESS, Luke A.; STEWART, Lesley A.; THOMAS, James; TRICCO, Andrea C.; WELCH, Vivian A.; WHITING, Penny; MOHER, David. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, v. 372, n71, 2021. DOI: 10.1136/bmj.n71.

FRÍAS, Juan P.; DAVIES, Melanie J.; ROSENSTOCK, Julio; PÉREZ MANGHI, Federico C.; FERNÁNDEZ LANDÓ, Laura; BERGMAN, Brandon K.; LIU, Bing; CUI, Xuewei; BROWN, Katelyn. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, v. 385, n. 6, p. 503–515, 2021. DOI: 10.1056/NEJMoa2107519. PMID: 34170647.

LUDVIK, Bernhard; GIORGINO, Francesco; JÓDAR, Esteban; FRÍAS, Juan P.; FERNÁNDEZ LANDÓ, Laura; BROWN, Katelyn; BRAY, Ross; RODRÍGUEZ, Ángel. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, v. 398, n. 10300, p. 583–598, 2021. DOI: 10.1016/S0140-6736(21)01443-4.

DEL PRATO, Stefano; KAHN, Steven E.; PAVO, Imre; WEERAKKODY, Govinda J.; YANG, Zhengyu; DOUPIS, John; AIZENBERG, Diego; WYNNE, Alan G.; RIESMEYER, Jeffrey S.; HEINE, Robert J.; WIESE, Russell J. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet, v. 398, n. 10313, p. 1811–1824, 2021. DOI: 10.1016/S0140-6736(21)02188-7.

DAHL, Dominik; ONISHI, Yukiko; NORWOOD, Paul; HUH, Ruth; BRAY, Ross; PATEL, Hiren; RODRÍGUEZ, Ángel. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA, v. 327, n. 6, p. 534–545, 2022. DOI: 10.1001/jama.2022.0078.

JASTREBOFF, Ania M.; ARONNE, Louis J.; AHMAD, Nadia N.; WHARTON, Sean; CONNERY, Lisa; ALVES, Breno; KIYOSUE, Arihiro; ZHANG, Shuyu; LIU, Bing; BUNCK, Mathijs C.; STEFANSKI, Adam. Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, v. 387, n. 3, p. 205–216, 2022. DOI: 10.1056/NEJMoa2206038.

GARVEY, W. Timothy; FRÍAS, Juan P.; JASTREBOFF, Ania M.; LE ROUX, Carel W.; SATTAR, Naveed; AIZENBERG, Diego; MAO, Huzhang; ZHANG, Shuyu; AHMAD, Nadia N.; BUNCK, Mathijs C.; BENABBAD, Imane; ZHANG, Xiaotian M. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, v. 402, n. 10402, p. 613–626, 2023. DOI: 10.1016/S0140-6736(23)01200-X.

WADDEN, Thomas A.; CHAO, Ariana M.; MACHINENI, Sriram; KUSHNER, Robert; ARD, Jamy; SRIVASTAVA, Gitanjali; HALPERN, Bruno; ZHANG, Shuyu; CHEN, Jiaxun; BUNCK, Mathijs C.; AHMAD, Nadia N.; FORRESTER, Tammy. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine, v. 29, n. 11, p. 2909–2918, 2023. DOI: 10.1038/s41591-023-02597-w.

RUBINO, Domenica M.; PEDERSEN, Sue D.; CONNERY, Lisa; CAO, Dachuang; CHIGUTSA, Farai; STEFANSKI, Adam; FRASEUR BRUMM, Julia; GRIFFIN, Ryan; GERBER, Claire. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes, Obesity and Metabolism, v. 27, n. 4, p. 1826–1835, 2025. DOI: 10.1111/dom.16176.

LIU, Liyuan. A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database. Frontiers in Pharmacology, v. 15, 1397029, 2024. DOI: 10.3389/fphar.2024.1397029.

OU, Yingyong; CUI, Zhiwei; LOU, Siyu; ZHU, Chengyu; CHEN, Junyou; ZHOU, Linmei; ZHAO, Ruizhen; WANG, Li; ZOU, Fan. Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups. Frontiers in Pharmacology, v. 15, 1463657, 2024. DOI: 10.3389/fphar.2024.1463657.

GUO, Xinghua; ZHANG, Jiahua; LI, Qisen; YE, Zhiqiang; YUAN, Shengyong. Safety profile of tirzepatide in real-world clinical practice: a pharmacovigilance study using the FAERS database. Diabetes, Obesity and Metabolism, v. 28, n. 10, p. 8936–8945, 2026. DOI: 10.1111/dom.71025.

KUBOTA, Mitsunobu; YAMAMOTO, Kazuki; YOSHIYAMA, Sayo. Effect on hemoglobin A1c (HbA1c) and body weight after discontinuation of tirzepatide, a novel glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist: a single-center case series study. Cureus, v. 15, n. 10, e46490, 2023. DOI: 10.7759/cureus.46490.

CHEN, Congling; YING, Zhen; TANG, Qi; ZHAO, Lin; LU, Yibing; FAN, Xiaofang; XU, Lan; SI, Si; LI, Yuanyuan; XU, Jiawei; WANG, Yihua; DONG, Yu; LI, Xiaoying; CHEN, Ying. Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial. Life Metabolism, v. 4, n. 5, loaf024, 2025. DOI: 10.1093/lifemeta/loaf024.

HORN, Deborah B.; LINETZKY, Bruno; DAVIES, Melanie J.; LAFFIN, Luke J.; WANG, Hui; MURPHY, Madhumita A.; ZIMNER-RAPUCH, Sarah; LAU, Eva; ARAD, Avigdor D.; LEE, Clare J. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial. JAMA Internal Medicine, v. 186, n. 2, p. 157–167, 2026. DOI: 10.1001/jamainternmed.2025.6112.

HORN, Deborah B.; ARONNE, Louis J.; WHARTON, Sean; BAYS, Harold E.; LE ROUX, Carel W.; SRINATH, Reshmi; GOMEZ-VALDERAS, Elisa; ARAD, Avigdor D.; DAS, Sagar; DUNN, Julia P.; RIBEIRO, Anderson; GLASS, Leonard C.; LEE, Clare J. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, v. 407, n. 10545, p. 2305–2318, 2026. DOI: 10.1016/S0140-6736(26)00656-2.

MISHRA, Rahul; RAJ, Rishi; ELSHIMY, Ghada; ZAPATA, Isain; KANNAN, Lakshmi; MAJETY, Priyanka; EDEM, Dinesh; CORREA, Ricardo. Adverse events related to tirzepatide. Journal of the Endocrine Society, v. 7, n. 4, bvad016, 2023. DOI: 10.1210/jendso/bvad016. PMID: 36789109.

TONG, Keke; YIN, Shuang; YU, Yunfeng; YANG, Xinyu; HU, Gang; ZHANG, Fei; LIU, Zhenjie. Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: a meta-analysis and trials sequential analysis. Medicine (Baltimore), v. 102, n. 43, e35488, 2023. DOI: 10.1097/MD.0000000000035488. PMID: 37904345.

GASBJERG, Lærke S.; ROSENKILDE, Mette M.; MEIER, Juris J.; HOLST, Jens J.; KNOP, Filip K. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide. Diabetes, Obesity and Metabolism, v. 25, n. 11, p. 3079–3092, 2023. DOI: 10.1111/dom.15216.

LIU, Qiyuan Keith. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology, v. 15, 1431292, 2024. DOI: 10.3389/fendo.2024.1431292. PMID: 39114288.

HEISE, Tim; MARI, Andrea; DEVRIES, J. Hans; URVA, Shweta; LI, Jing; PRATT, Edward J.; COSKUN, Tamer; THOMAS, Melissa K.; MATHER, Kieren J.; HAUPT, Axel; MILICEVIC, Zvonko. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. The Lancet Diabetes & Endocrinology, v. 10, n. 6, p. 418–429, 2022. DOI: 10.1016/S2213-8587(22)00085-7.

JALLEH, Ryan J.; RAYNER, Chris K.; HAUSKEN, Trygve; JONES, Karen L.; CAMILLERI, Michael; HOROWITZ, Michael. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. The Lancet Gastroenterology & Hepatology, v. 9, n. 10, p. 957–964, 2024. DOI: 10.1016/S2468-1253(24)00188-2. PMID: 39096914.

JALLEH, Ryan J.; MARATHE, Chinmay S.; RAYNER, Christopher K.; JONES, Karen L.; UMAPATHYSIVAM, Mahesh M.; WU, Tongzhi; QUAST, Daniel R.; PLUMMER, Mark P.; NAUCK, Michael A.; HOROWITZ, Michael. Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility. Endocrinology, v. 166, n. 1, bqae155, 2025. DOI: 10.1210/endocr/bqae155. PMID: 39568409.

DRUCKER, Daniel J. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, v. 57, 101351, 2022. DOI: 10.1016/j.molmet.2021.101351. PMID: 34626851.

WILDING, John P. H.; BATTERHAM, Rachel L.; DAVIES, Melanie; VAN GAAL, Luc F.; KANDLER, Kristian; KONAKLI, Katerina; LINGVAY, Ildiko; MCGOWAN, Barbara M.; KALAYCI ORAL, Tugce; ROSENSTOCK, Julio; WADDEN, Thomas A.; WHARTON, Sean; YOKOTE, Koutaro; KUSHNER, Robert F. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, v. 24, n. 8, p. 1553–1564, 2022. DOI: 10.1111/dom.14725. PMID: 35441470.

BUDINI, Brajan; LUO, Steven; TAM, Martin; STEAD, Isabel; LEE, Andrew; AKRAMI, Angelica; VIDAL-PUIG, Antonio; PARK, Adrian. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine, v. 93, 103796, 2026. DOI: 10.1016/j.eclinm.2026.103796. PMID: 41938838.

SUMITHRAN, Priya; PROIETTO, Joseph. The defence of body weight: a physiological basis for weight regain after weight loss. Clinical Science, v. 124, n. 4, p. 231–241, 2013. DOI: 10.1042/CS20120223. PMID: 23126426.

GREENWAY, Frank L. Physiological adaptations to weight loss and factors favouring weight regain. International Journal of Obesity, v. 39, n. 8, p. 1188–1196, 2015. DOI: 10.1038/ijo.2015.59. PMID: 25896063.

ROSENBAUM, Michael; LEIBEL, Rudolph L. 20 years of leptin: role of leptin in energy homeostasis in humans. Journal of Endocrinology, v. 223, n. 1, p. T83–T96, 2014. DOI: 10.1530/JOE-14-0358. PMID: 25063755.

SUMITHRAN, Priya; PRENDERGAST, Luke A.; DELBRIDGE, Elizabeth; PURCELL, Katrina; SHULKES, Arthur; KRIKETOS, Adamandia; PROIETTO, Joseph. Long-term persistence of hormonal adaptations to weight loss. The New England Journal of Medicine, v. 365, n. 17, p. 1597–1604, 2011. DOI: 10.1056/NEJMoa1105816. PMID: 22029981.

STROHACKER, Kelley; MCCAFFERY, Jeanne M.; MACLEAN, Paul S.; WING, Rena R. Adaptations of leptin, ghrelin or insulin during weight loss as predictors of weight regain: a review of current literature. International Journal of Obesity, v. 38, n. 3, p. 388–396, 2014. DOI: 10.1038/ijo.2013.118. PMID: 23801147.

DULLOO, Abdul G. Physiology of weight regain: lessons from the classic Minnesota Starvation Experiment on human body composition regulation. Obesity Reviews, v. 22, supl. 2, e13189, 2021. DOI: 10.1111/obr.13189. PMID: 33543573.

VAN BAAK, Marleen A.; MARIMAN, Edwin C. M. Obesity-induced and weight-loss-induced physiological factors affecting weight regain. Nature Reviews Endocrinology, v. 19, p. 655–670, 2023. DOI: 10.1038/s41574-023-00887-4

ARONNE, Louis J.; HALL, Kevin D.; JAKICIC, John M.; LEIBEL, Rudolph L.; LOWE, Michael R.; ROSENBAUM, Michael; KLEIN, Samuel. Describing the weight-reduced state: physiology, behavior, and interventions. Obesity, v. 29, supl. 1, p. S9–S24, 2021. DOI: 10.1002/oby.23086. PMID: 33759395.

MELBY, Christopher L.; PARIS, Hunter L.; FORIGHT, Rebecca M.; PETH, James. Attenuating the biologic drive for weight regain following weight loss: must what goes down always go back up? Nutrients, v. 9, n. 5, p. 468, 2017. DOI: 10.3390/nu9050468. PMID: 28481261

MÜLLER, Manfred J.; BOSY-WESTPHAL, Anja. Adaptive thermogenesis with weight loss in humans. Obesity, v. 21, n. 2, p. 218–228, 2013. DOI: 10.1002/oby.20027. PMID: 23404923.

ROSENBAUM, Michael; VANDENBORNE, Krista; GOLDSMITH, Rochelle; SIMONEAU, Jean-Aimé; HEYMSFIELD, Steven; JOANISSE, Denis R.; HIRSCH, Jules; MURPHY, Ellen; MATTHEWS, Dwight; SEGAL, Karen R.; LEIBEL, Rudolph L. Effects of experimental weight perturbation on skeletal muscle work efficiency in human subjects. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, v. 285, n. 1, p. R183–R192, 2003. DOI: 10.1152/ajpregu.00474.2002. PMID: 12609816.

NUNES, Camila L.; CASANOVA, Nuno; FRANCISCO, Rita; BOSY-WESTPHAL, Anja; HOPKINS, Mark; HANKERSON, Sara; CARVALHO, João; SARDINHA, Luís B.; SILVA, Analiza M. Does adaptive thermogenesis occur after weight loss in adults? A systematic review. British Journal of Nutrition, v. 127, n. 3, p. 451–469, 2022. DOI: 10.1017/S0007114521001094. PMID: 33762040.

TZANG, Chih-Chen; WU, Pei-Hsun; LUO, Chiao-An; CHEN, Zi-Ting; LEE, Yi-Ting; HUANG, Ewen Shengyao; KANG, Yuan-Fu; LIN, Wei-Chen; TZANG, Bor-Show; HSU, Tsai-Ching. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine. 2025;90:103680. doi:10.1016/j.eclinm.2025.103680. PMID: 41399474.

Downloads

Publicado

2026-10-14

Como Citar

Alves, P. H., Santana, R. R., Oliveira, K. C., Avelar, I. S. de, Ribeiro, J. P., Souza, Álvaro P. S., … Barbosa, M. F. de J. M. (2026). Tirzepatida: efeitos adversos e reganho ponderal após a interrupção do tratamento — revisão integrativa. Brazilian Journal of Implantology and Health Sciences , 8(10), 1107–1142. https://doi.org/10.36557/2674-8169.2026v8n10p1107-1142